MeSH tree: C15.604.515.569.480.150.585
Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma (DLBCL) had shorter survival times than patients without a mental health diagnosis, according to a retrospective study led by Dana-Farber ...
Jun 2, 2023
0
48
The key to understanding how the most aggressive lymphomas arise and resist current therapies may lie in mutations that disrupt a critical natural selection process among antibody-producing B cells, according to a multi-institutional ...
Jan 24, 2023
0
48
A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The current findings ...
Jan 9, 2023
0
50
Patient-reported outcomes from individuals diagnosed with relapsed or refractory large B-cell lymphoma revealed that those who received axicabtagene ciloleucel (axi-cel) immunotherapy experienced higher quality of life than ...
Jan 4, 2023
0
66
If someone is stricken with a blood cancer or life-threatening clot, they'll probably fare better if they are white and wealthy, three new studies show.
Dec 12, 2022
0
19
The treatment of blood cancers has dramatically improved in the last five years, thanks to a new class of cancer immunotherapies called CAR-T cell therapy. This therapy—which involves engineering a patient's own T cells in ...
Sep 13, 2022
0
76
Researchers at Stanford University have developed "decoy receptor" molecules that inhibit the growth of both multiple myeloma (MM) and diffuse large B cell lymphoma (DLBCL) in mice. The molecules, described in a study to ...
Jul 26, 2022
0
68
